Endocrine Abstracts

Data regarding hyperthyroidism is lacking in Nepal. We did a retrospective analysis of clinical profile and treatment modalities of hyperthyroidism patients in our center.

Methodology: Retrospective data of 132 hyperthyroidism patients between March 2013 and April 2014 at Kathmandu Diabetes and Thyroid Center were analyzed. These patients’ records were followed up for one year.

Results: Hyperthyroidism was common in females (73.5%). Graves’ disease (GD) was the most common cause (60.6%), then thyroiditis (30.3%), toxic multinodular goiter (Toxic MNG) (5.3%) and autonomously functioning thyroid nodules (AFTN) (3.8%). Mean age of the patients (years) were 36.0±12.2 (GD), 38.7±10.7 (thyroiditis), 52.4±18.9 (Toxic MNG) and 52.6±17.8 (AFTN). 11 (13.8%) patients with GD had Graves’ ophthalmopathy. Subacute thyroiditis was seen in 13% with thyroiditis and rest had painless thyroiditis. In GD, 80% patients were treated with antithyroid drugs (ATDs) initially. 55% patients received Radioactive Iodine ablation (RAIA) in GD ultimately. 4 patients required a second dose of RAI. The mean duration to become hypothyroid after RAIA was 4.1±1.7 months. The hypothyroid patients required mean dose of 68.7±18.4 μg of thyroxine. All seven patients of toxic MNG were treated with ATDs. Of 5 AFTN patients, 2 had RAIA, 1 had hemithyroidectomy and rest treated with ATDs.

Conclusion: Hyperthyroidism was found to be most common in females. GD was the most common cause. Most patients with GD were treated with ATDs initially but 55% had RAIA done ultimately. ATDs were also commonly used in toxic MNG and AFTN.